NCT07711652

Brief Summary

Evidence regarding the ergogenic effects of caffeine is well-established in young adults, but evidence in older adults remains scarce, particularly during dynamic resistance exercise. Therefore, this study compared the effects of acute caffeine ingestion on upper- and lower-body muscular strength and endurance performance according to age, in young and older adults.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 14, 2023

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 21, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2026

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 13, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 17, 2026

Completed
Last Updated

July 17, 2026

Status Verified

July 1, 2026

Enrollment Period

2.9 years

First QC Date

July 13, 2026

Last Update Submit

July 13, 2026

Conditions

CaffeinePlacebo

Outcome Measures

Primary Outcomes (4)

  • Mean velocity at different %1RM

    Mean velocity at different %1RM (25-90%1RM)

    Through study completion, an average of 3 weeks

  • Number of repetitions performed in 1 set at 65%1RM until task failure

    In bench press and back squat exercises

    Through study completion, an average of 3 weeks

  • Bar velocity displacement performed in 1 set at 65%1RM until task failure

    In bench press and back squat exercises

    Through study completion, an average of 3 weeks

  • handgrip and isometric mid-thigh pull tests

    N generated

    Through study completion, an average of 3 week

Secondary Outcomes (3)

  • cyp1a2 polymorphism

    Before the beginning of the trial

  • Mood state (tension, depression, anger, vigor, fatigue and confusion)

    Through study completion, an average of 3 weeks

  • Adverse effects

    Through study completion, an average of 3 weeks

Study Arms (4)

Placebo - Young Adults

PLACEBO COMPARATOR

Placebo (3 mg/kg maltodextrin) in young adults

Dietary Supplement: Placebo

Placebo - Older Adults

PLACEBO COMPARATOR

Placebo (3 mg/kg maltodextrin) in older adults

Dietary Supplement: Placebo

Caffeine - Young Adults

EXPERIMENTAL

Acute caffeine intake (3 mg/kg) in young adults

Dietary Supplement: Caffeine

Caffeine - Older Adults

EXPERIMENTAL

Acute caffeine intake (3 mg/kg) in older adults

Dietary Supplement: Caffeine

Interventions

CaffeineDIETARY_SUPPLEMENT

Acute caffeine intake (3 mg/kg)

Caffeine - Older AdultsCaffeine - Young Adults
PlaceboDIETARY_SUPPLEMENT

(3 mg/kg maltodextrin)

Placebo - Older AdultsPlacebo - Young Adults

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between ≥18 and 35 years in young adults and ≥ 55 and 80 years in older adults.
  • Body mass index (BMI) lower than 25 kg/m².
  • Physically active subjects (≥150 min/week of moderate exercise).
  • Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
  • Participants capable of performing the tests.

You may not qualify if:

  • History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
  • Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
  • Body mass index (BMI) ≥ 25 kg/m².
  • Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
  • Performing strenuous exercise within 48 hours prior to the tests.• Failing to replicate the same food intake on the two experimental days.
  • Consuming caffeine after 6 PM on the day prior to training or testing.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, 28805, Spain

Location

MeSH Terms

Interventions

Caffeine

Intervention Hierarchy (Ancestors)

XanthinesAlkaloidsHeterocyclic CompoundsPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Statisian
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 13, 2026

First Posted

July 17, 2026

Study Start

January 14, 2023

Primary Completion

December 21, 2025

Study Completion

April 30, 2026

Last Updated

July 17, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will share

Locations

ES(1)